Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alzamend Neuro Inc

ALZN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.55

▲ +6.53%

Market Cap $7.43M · Vol 5.03K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$7.43M

Micro Cap

Div Yield

N/A

EPS Growth

+1.14%

YoY

RSI (14)

68.42

Momentum

Beta

0.22

vs Market

52W High

$2.68

42.16% below

52W Low

$0.85

82.35% above

Volume

5.03K

Avg 9.87K

P/B

6.62

Price-to-book

ROE

N/A

Return on equity

Free Float

97.32%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Alzamend Neuro Inc (ALZN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALZN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+13.14%

+28.10%

+50.49%

-4.91%

YTD

-14.84%

-36.21%

-99.63%

-99.97%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-8,772,380.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-262.55% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	6.62
P/FCF	N/A
EPS Growth	+1.14%
Outstanding Shares	4.79M

Technical Indicators

50-Day SMA	$1.27
200-Day SMA	$1.66
RSI (14)	68.42
Beta	0.22
52-Week High	$2.68
52-Week Low	$0.85

Volume Today	5.03K
Avg Daily Volume (30D)	9.87K
Relative Volume	0.51x
Volatility (10D)	59.26
Volatility (30D)	51.68
Free Float	97.32%

Analyst Consensus

BUY

Current Price $1.55

Mean Target $25.00

52W Low$0.85 52W High$2.68

Current

Target

$0.85 $2.68

Current Analyst target

+1,512.90% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00ZMXG7N7

ISINUS02262M6057

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateSep 8, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.